SUD Pharmacotherapy Developers
Commercial sector
SUD Pharmacotherapy Developers
Companies developing or commercializing medications (small molecules, biologics, or novel mechanisms) for the treatment of opioid, stimulant, alcohol, or cannabis use disorders. This includes approved formulations of buprenorphine, methadone, and naltrexone, as well as clinical-stage programs targeting novel receptors (kappa, orexin, GLP-1, neuroimmune, psychedelic-derived) or repurposed agents for stimulant and cannabis use disorders.
Companies55
Commercial products151
Technology classes8
Countries12
Patents945
Profiled companies
Products
- IndiviorUnited States8
- OrexoSweden9
- AlkermesIreland2
- BraeburnUnited States1
- EthypharmFrance2
- Sparian BiosciencesUnited States5
+ 49 more